Kazumi Mori‐Anai

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial

Takashi Wada, Kazumi Mori‐Anai, Yutaka Kawaguchi et al. · Journal of Diabetes Investigation · 2021 · 28 citations · Full text

Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study in Japan

Takashi Wada, Kazumi Mori‐Anai, Akiko Takahashi et al. · Journal of Diabetes Investigation · 2022 · 22 citations · Full text

Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance

Nobuya Inagaki, Masaomi Nangaku, Yasushi Sakata et al. · Advances in Therapy · 2021 · 13 citations · Full text